Equities

Avacta Group PLC

AVCT:LSE

Avacta Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)46.75
  • Today's Change1.00 / 2.19%
  • Shares traded2.50m
  • 1 Year change-61.99%
  • Beta1.8556
Data delayed at least 20 minutes, as of May 01 2024 17:08 BST.
More ▼

Profile data is unavailable for this security.

About the company

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

  • Revenue in GBP (TTM)16.03m
  • Net income in GBP-42.08m
  • Incorporated2003
  • Employees120.00
  • Location
    Avacta Group PLCUnit 20, Ash WayWETHERBY LS23 7FAUnited KingdomGBR
  • Phone+44 19 0421 7070Fax+44 84 4414 0453
  • Websitehttps://avacta.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AVCT:LSE since
announced		Transaction
value
Coris BioConcept SPRLDeal completed01 Jun 202301 Jun 2023Deal completed-56.71%12.93m
Data delayed at least 20 minutes, as of May 01 2024 17:08 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Scancell Holdings Plc0.00-11.32m82.78m51.0082.78m51.00
Futura Medical PLC3.10m-6.51m99.33m12.0099.33m12.00
Faron Pharmaceuticals Oy0.00-26.42m104.48m34.00104.48m34.00
4Basebio PLC354.00k-6.28m137.02m--137.02m--
Allergy Therapeutics plc53.26m-50.22m138.23m635.00138.23m635.00
Animalcare Group Plc74.35m1.20m139.45m220.00139.45m220.00
Avacta Group Plc16.03m-42.08m164.26m120.00164.26m120.00
Alliance Pharma plc170.05m-7.06m183.74m249.00183.74m249.00
hVIVO PLC56.04m16.12m191.86m274.00191.86m274.00
Bioventix PLC13.60m8.67m223.14m16.00223.14m16.00
Data as of May 01 2024. Currency figures normalised to Avacta Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

26.56%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 202423.12m6.60%
Jarvis Investment Management Ltd.as of 01 Apr 202421.47m6.13%
Conifer Management LLCas of 28 Apr 202311.85m3.38%
Baillie Gifford & Co.as of 28 Apr 202310.12m2.89%
IG Markets Ltd.as of 01 Apr 20247.96m2.27%
HSBC Global Asset Management (UK) Ltd.as of 01 Apr 20246.04m1.72%
Unicorn Asset Management Ltd.as of 01 Apr 20243.90m1.11%
Premier Fund Managers Ltd.as of 01 Apr 20243.65m1.04%
HSBC Bank Plc (Market-Maker)as of 01 Apr 20242.62m0.75%
AXA Investment Managers UK Ltd.as of 29 Feb 20242.34m0.67%
More ▼
Data from 31 Dec 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.